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AbstrAct
The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized 
the treatment of chronic myeloid leukemia (CML). However current unmet clinical 
needs include combating activation of additional survival signaling pathways in 
persistent leukemia stem cells after long-term TKI therapy. A ubiquitous signaling 
alteration in cancer, including CML, is activation of reactive oxygen species (ROS) 
signaling, which may potentiate stem cell activity and mediate resistance to both 
conventional chemotherapy and targeted inhibitors. We have developed a novel 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor, imipramine 
blue (IB) that targets ROS generation. ROS levels are known to be elevated in CML 
with respect to normal hematopoietic stem/progenitor cells and not corrected by TKI. 
We demonstrate that IB has additive benefit with nilotinib in inhibiting proliferation, 
viability, and clonogenic function of TKI-insensitive quiescent CD34+ CML chronic 
phase (CP) cells while normal CD34+ cells retained their clonogenic capacity in 
response to this combination therapy in vitro. Mechanistically, the pro-apoptotic 
activity of IB likely resides in part through its dual ability to block NF-κB and re-activate 
the tumor suppressor protein phosphatase 2A (PP2A). Combining BCR-ABL1 kinase 
inhibition with NADPH oxidase blockade may be beneficial in eradication of CML and 
worthy of further investigation. 
IntroductIon
Genomic instability underpins cancer. Point 
mutations, double strand breaks and translocations arising 
from oxidative stress are commonplace with elevated 
reactive oxygen species (ROS) generated by mitochondrial 
respiration mediating such DNA damage [1,  2]. Genetic 
lesions are of particular significance in stem cells. 
Endosteal niches in which hematopoietic stem cells 
(HSC) reside provide a hypoxic protective environment 
conducive to maintaining low ROS and consequently 
high reconstitution function [3]. Quiescent HSC, despite 
their relatively high mitochondrial content, exist in a low 
energy state that restricts DNA damage from replication 
stress. Proliferating (self-renewing) HSC switch to a high 
energy state, whereby mitochondrial respiration generates 
ROS. Mitochondrial ROS can stimulate nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases [4]. 
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Pharmacological targeting of this cycle of ROS production 
to neutralise its DNA damaging effects and limit genomic 
instability is an attractive proposition in cancer of stem 
cell origin, such as chronic myeloid leukemia (CML). 
CML is a myeloid neoplasm characterized by 
the BCR-ABL1 fusion oncogene, a constitutively active 
tyrosine kinase. Because this kinase is unique to tumor 
cells, it provided an attractive target for pharmacologic 
development of small molecule, orally bioavailable 
tyrosine kinase inhibitors (TKI) [5]. Imatinib was the first 
clinically used TKI, and the CML treatment paradigm led 
to the development of targeted therapies for other driver 
mutations, such as Braf in melanoma, and EGFR and 
Alk mutations in lung cancer [6]. While TKIs can control 
chronic phase (CP) CML for several years, progression 
through accelerated phase (AP) to terminal blast crisis 
(BC) can still occur [7]. Even maximal TK inhibition is 
incapable of completely eliminating CML stem cells [8]. 
Hamilton et al., noted that deprivation of growth factors 
and addition of the potent dual Src-Abl kinase inhibitor, 
dasatinib resulted in the enrichment of primitive stem cells 
capable of proliferation once dasatinib is withdrawn in vitro 
[9]. Although clinical resistance is a relatively rare event (in 
up to 20% of cases), many mechanisms including mutation 
of BCR-ABL1, especially of the ATP binding pocket [6] or 
activation of additional signaling pathways independent of 
BCR-ABL1have been identified in CML [5, 10]. 
The most primitive (lineage negative, CD34+ CD38−/+) 
leukemia stem and progenitor cells (LSC/LPC) from CP 
CML patients were found to have higher (2- to 4-fold) 
ROS levels compared to normal HSC, which were not 
corrected by inhibition of BCR-ABL1 kinase activity with 
TKI [11]. Interestingly, poor responders to TKI therapy 
were found to have higher levels of ROS in their LSC at 
diagnosis than good responders who went on to achieve 
complete cytogenetic response (CCR) and major/complete 
molecular response (MMR/CMR) [11]. Persistence of 
TKI-insensitive LSC under such long-term oxidative 
stress will risk expansion of dominant TKI-resistant 
clones and, perhaps, evolution of BC. Indeed G:C to A:T 
substitutions, as in the E255K and T315I TKI-resistant 
BCR-ABL1 kinase mutations, are commonly consequent 
of ROS-induced DNA damage [11]. Skorski’s group 
identified electron leakage from mitochondrial respiratory 
chain complex III (MRC-cIII) as a major source of ROS 
mediated DNA damage in CML LSC and targeted its 
activity with an inhibitor of Rac2, a GTPase that can 
modify mitochondrial membrane potential and electron 
flow through MRC [12]. 
The ‘reactive oxygen driven’ solid tumor has 
previously been described, characterized by high levels 
of superoxide generation in tumor cells [13] that are often 
refractory to conventional chemotherapy, targeted therapy 
and radiation [2, 14]. Previously we have demonstrated 
the efficacy of the synthetic NADPH oxidase inhibitor 
imipramine blue (IB) to block the invasion of glioblastoma 
multiforme (GBM) into the brain parenchyma [15], 
and therefore, prolong survival in animal models likely 
through eradication of ROS-driven GBM stem cells. As 
the role of ROS in hematopoietic tumors is clearly also 
now emerging [16, 17], we responded to the call for ROS 
inhibitors as novel therapies for CML. We hypothesized 
that IB could be suitable for use in CML, not just by 
limiting genomic instability and disease progression 
to BC, but moreover as a potential LSC toxic agent. In 
this paper, we demonstrated that IB curbs survival of 
CML LSC/LPCs, and that its effect was potentiated by 
co-treatment with TKIs (i.e. nilotinib). Mechanistically, we 
showed that the pro-apoptotic activity of IB likely resides in 
its propensity towards being a PP2A activating drug (PAD) 
[8]. Combination therapy with a NADPH oxidase inhibitor 
and nilotinib may help prevent emergence of TKI-resistance 
and/or neutralise TKI-insensitive CML LSC. This is 
achieved by blockade of LSC specific ROS signaling 
alongside quenching of oncoprotein activity, respectively. 
Such a dual approach may be applicable to other ROS-driven 
hematopoietic malignancies with different driver oncogenic 
fusions and associated genomic instability.
results 
Ib reduces numbers of viable primary 
cd34+cMl˗cP cells and bcr-Abl1+ human 
bc cell lines in vitro
 We first wished to demonstrate clinically relevant 
activity of IB in CML cells, so primary CD34+ CML-CP 
cells and BCR-ABL1+ human CML-BC cell lines were 
incubated with the drug in vitro and total viable cell 
counts performed by Trypan Blue dye exclusion after 
72 h. The IC50 of IB was similar in each of these cell 
contexts at 1.32 ± 0.25 µM for CD34+ CML-CP cells 
(n = 3) (Figure 1A), 1.13 ± 0.07 µM for KCL22WT cell 
line (Figure 1B), and approximately 1.65 µM for imatinib 
resistant KCL22T315I cells (Supplementary Figure S1A). 
Primary CD34+ CML-CP cells were more resistant 
to apoptosis induction by IB than BCR-ABL1WT+ CML-BC 
cell lines, nonetheless, the percentage of Annexin V+ cells 
increased in a concentration dependent manner in response 
to IB (Figure 2A–2C), and to a magnitude far greater 
than can be achieved with TKI. Collated data from flow 
cytometry experiments with 3 independent CD34+ CML-CP 
cell samples showed 26 ± 1 versus 63 ± 16 % Annexin 
V+ (NDC versus 2 µM IB; p = 0.04, Figure 2A). In our 
hands 3 µM nilotinib on average induces only about 5–10% 
apoptosis above background level in NDC (DMSO) in 
CD34+ CML-CP cells after 72 h in vitro (data not shown). 
Interestingly apoptosis was not different from 
background level (NDC) in KCL22WT cells at the 
respective IC50 for viable cell counts for IB (approx. 
1 µM) which may suggest cell cycle arrest without kill 
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at this concentration (Figure 2B). However just a small 
increase to 1.5 µM IB approximately doubled the level of 
apoptosis with respect to background (46 v 25 % Annexin 
V+, IB v NDC) in imatinib resistant KCL22T315I cells, 
whereas it was only 29% with 100 nM ponatinib, a 
next generation TKI to which these cells are sensitive 
(Supplementary Figure S1B).
Ib in combination with nilotinib inhibits 
proliferation of cd34+ cMl-cP cells and is 
synergistic against bcr-Abl1+ cells in vitro
We were interested to know if there was any 
combination effect between IB and TKI on BCR-ABL1+ 
cells in vitro. Primary CD34+ CML-CP cells were 
Figure 1: Imipramine blue (Ib) decreases viable bcr-Abl1+ cMl cell number in a concentration dependent manner 
with respect to untreated control. (A) The number of viable CD34+ CML-CP cells remaining after 72 h in culture with increasing 
concentrations of IB, as counted by Trypan Blue dye exclusion method, was normalized to the No Drug Control (NDC) for each of three 
patients (solid line CML003; dashed line CML388; dotted line CML391). Minimum 5 data points per curve, curve fit r2 = 0.84, 0.97 and 
0.94 for CML003, 388 and 391, respectively). (b) KCL22 cells with un-mutated (wildtype, WT) BCR-ABL1 were cultured with increasing 
concentration of IB and counted after 72 h (mean ± SEM of 3 repeat experiments). 
Figure 2: Apoptosis response of bcr-Abl1+ cells to imipramine blue (Ib). IB treated (A) primary CD34+ CML-CP cells 
(n = 3), (b) KCL22WT cells (mean ± SEM; n = 3 experiments), were stained with Annexin V and propidium iodide to assess apoptotic 
response to the drug by flow cytometry. (c) Illustrative flow cytometry dot plots of primary CD34+ CML-CP cells (CML391) showing a 
concentration dependent apoptotic response to IB after 72 h. 
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treated in vitro with nilotinib (1 µM) in combination 
with IB (1 µM). Induction of apoptosis with the 
combination of nilotinib plus IB was clearly markedly 
enhanced with respect to either drug as a single agent 
(representative example in Figure 3A) although this did 
not reach statistical significance owing to inter-patient 
variability in extent of response. It was noted that some 
cells counted under phase contrast microscopy and 
scored as viable owing to Trypan Blue dye exclusion 
were in fact committing to apoptosis and/or dying 
(Figure 3B and 3C). Hence it was important to assess 
their functional capacity (i.e. clonogenicity) after drug 
treatment. Surviving cells were plated into colony 
forming cell (CFC) assay. As each well started with the 
same cell number before drug addition, each had the 
same expansion potential, and so taking an equal fixed 
volume from each well to set up CFC at the end of a 
72 h drug exposure experiment reflects drug activity 
in that time frame. It can be seen clearly that the few 
remaining CD34+ CML-CP cells could not divide to 
form colonies after combination treatment and so had 
been severely functionally compromised (Figure 3D). 
The colonies formed were BCR-ABL1+ by fluorescence 
in situ hybridization (FISH) (Figure 3E).
When assayed at fixed ratio according to the method 
of Chou and Talalay in BCR-ABL1+ K562WT cells, 
nilotinib and IB in combination were synergistic with 
combination indices (CI) consistently less than 1 (Table 1).
cell division tracking of primary cFse labelled 
cd34+ cMl-cP cells 
We have previously shown that TKI can hold CD34+ 
CML-CP cells out of cycle in vitro without killing them 
[21]. To determine if this ‘anti-proliferative’ phenomenon 
was also true for IB, cell division tracking was performed 
using the vital fluorescent stain, CFSE then assaying 
surviving cells for colony forming ability (CFC). After 
72 h in culture, CFSE loaded CML-CP cells were stained 
with anti-CD34-APC and the cells in the viable gate (as 
assessed by FSC/SSC) were analysed for cell division 
history. Firstly, it could be seen that with CML cells, the 
total number of live events was reduced with IB treatment 
with respect to either nilotinib or DMSO (NDC) control, 
and more so with the combination (Figure 4; p = 0.006 
combination v NDC). It may also be inferred that the cells 
remaining ‘alive’ after IB treatment were more primitive 
i.e. in an early division by CFSE with higher CD34 
surface expression, than was seen with nilotinib treatment. 
However drug treatment had not enriched for CML 
stem/progenitor cells as the remaining few were 
non-functional primitive cells, as shown by compromised 
clonogenicity capacity in colony forming cell (CFC) assay 
(c.f. Figure 3D). 
From these cell division tracking experiments, 
an anti-proliferative effect in CML, that is restriction 
of cell division by IB alone and in combination with 
nilotinib may be presumed from the higher percentage 
of cells recovered in lower divisions in either of these 
drug conditions compared to no drug control (NDC) 
or nilotinib alone (Table 2; Supplemental Table S1). 
However, from the absolute number of cells recovered 
from the wells, calculated as the product of the percentage 
in gate multiplied by total viable cell count, with IB alone 
or in combination with nilotinib, the synthetic lethality is 
evident, that is while either drug alone may be compatible 
with viability, the combination of both leads to cell death. 
bcr-Abl1negative cd34+ cells retain their 
primitive function with Ib and nilotinib 
combination treatment 
We next needed to know if normal hematopoiesis 
may be affected by IB, so we modelled this in vitro 
using BCR-ABL1negative CD34+ cells which are immature 
hematopoietic cells lacking the causative oncogenic 
driver translocation. Gating on Annexin V/DAPI 
table 1: determination of synergy for the imipramine blue (Ib) plus nilotinib combination in 
K562 cells
nilotinib (µM) Ib (µM) Fa cI
0.0015 0.5 0.77 0.958
0.0015 1 0.96 0.97
0.003125 0.5 0.81 1.008
0.003125 1 0.98 0.811
0.00625 1 0.992 0.642
0.0125 0.5 0.94 0.975
0.0125 1 0.997 0.507
0.025 0.5 0.996 0.417
0.025 0.25 0.97 0.806
Fa Fraction affected; CI Combination Index.
Oncotarget51655www.impactjournals.com/oncotarget
double negative events for viable cells, the percentage 
live cells remaining in the well after treatment of 
BCR-ABL1negative (normal) CD34+ cells with 1 µM 
each of nilotinib and IB, was approximately half the 
untreated control (e.g. 84 v 38%; Figure 5A) which 
was a greater surviving fraction than seen with treated 
CML-CP cells (1%, c.f. Figure 3A; p = 0.001 CML 
versus normal). Moreover, the functional capacity 
(ability to form a colony in CFC assay) of surviving 
normal CD34+ cells was unaffected by either drug 
alone or combination (Figure 5B) whereas for CML-CP 
cells there were16 times fewer total CFC with the 
combination treatment compared to normal; average 4% 
(CML) versus 64% (normal) of respective NDC.
Ib blocks nF-κb activation in bcr-Abl1+ cells 
To determine whether IB inhibited key intracellular 
signaling pathways, we first examined the effect of 
IB on cytokine-induced activation of NF-κB. TNF-α 
led to prominent induction of NF-κB as assessed 
by electrophoretic mobility shift assay (EMSA) in 
BCR-ABL1+ KBM-5 cells (Figure 6). Pre-treatment with 
IB led to a concentration-dependent decrease in activated 
NF-κB, with a greater than 60% inhibition at 10 µM 
(Figure 6). A similar concentration-dependent decrease in 
MAP kinase activation was also seen. 
IB significantly increases PP2A activity in 
32d-bcr-Abl1 cells
Reactive oxygen species are known to inactivate 
many protein phosphatases through oxidation of sulfhydryl 
groups [18]. Because IB inhibits NADPH oxidase, we 
sought to investigate whether IB-induced apoptosis of CML 
stem/progenitor cells depends, at least in part, on inhibition 
of PP2A tumor suppressor activity as we previously 
reported in both TKI-resistant quiescent stem and progenitor 
cells from CML-CP and -BC patients [7, 19]. 
To determine whether IB acts as a PP2A-activating 
drug (PAD) [8], PP2A phosphatase activity was assessed 
in 32D-BCR-ABL1 myeloid cells exposed for 6h to IB 
(5 µM) (Figure 7). Untreated 32D-BCR-ABL1 cells were 
used as negative controls [19]. Treatment with IB restored 
PP2A activity in 32D-BCR-ABL1 cells (Figure 7) at levels 
higher than those observed in parental 32Dcl3 cells (not 
shown) and upon treatment of 32D-BCR-ABL1 cells with 
the potent PAD, FTY720 [9] (Figure 7). Thus, IB seems 
to exert its anti-leukemic activity, at least in part, through 
reactivation of PP2A.
In order to mechanistically show a role of PP2A, we 
treated cells with okadaic acid (OA), used at a concentration 
(0.25 nM) that reportedly inhibits PP2A activity only [9, 19], 
as well as genetically inhibiting PP2A by expressing the small 
T antigen (sT-Ag). Treatment with the PP2A inhibitor OA 
blunted the response to IB, while sT-Ag nearly completely 
blocked the response to IB. Thus, PP2A reactivation likely 
plays a major role in the activity of IB (Figure 8A).
To determine the pro-apoptotic activity of IB in 
both parental and BCR-ABL1-expressing 32Dcl3 cells, 
cells were incubated with the drug in vitro and viable 
cell counts performed after 24h using Annexin V staining 
(Figure 8B). The cells were treated with 5 µM of IB, 
0.25 nM of OA, and combination. 
dIscussIon 
CML was the first malignancy to be associated with 
a specific translocation, namely the Philadelphia (Ph) 
chromosome associated t(9;22) translocation. The ability 
of the BCR-ABL1 to serve as an oncogenic driver mutation 
has been elegantly described in both transplantation 
experiments and transgenic models. The causality of BCR-
ABL1 in myeloid malignancy served as the impetus to 
develop specific inhibitors of BCR-ABL1, beginning with 
imatinib, and followed with additional inhibitors to target 
both wild type and a multitude of mutant BCR-ABL1, 
table 2: Percentage of cells and absolute cell numbers recovered by division
cMl388 Viable cells 
(percentage in gate and absolute cell number)
division # 0 1 2 3, 4, 5
treatment % cell no. % cell no. % cell no. % cell no.
NDC 2.0 41 7.5 155 16.2 337 61.5 1276
nilotinib (1 µM) 10.5 74 22.5 159 29.2 206 24.8 175
IB (1 µM) 13.5 38 49.6 140 24.8 70 4.3 12
Combination 28.9 11 63.2 24 0 0 0 0
From these cell division tracking experiments, an anti-proliferative effect in CML that is restriction of cell division, of IB 
alone and in combination with nilotinib may be presumed from the higher percentage of cells recovered in lower divisions in 
either of these drug conditions compared to No Drug Control (NDC) or nilotinib alone. However, from the absolute number 
of cells recovered from the wells, calculated as the product of the percentage in gate multiplied by total viable cell count, with 
IB alone or in combination with nilotinib, the synthetic lethality is evident, that is when either drug alone may be compatible 
with viability but the combination of both leads to cell death. 
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including BCR-ABL1T315I. The discovery of leukemia stem 
cells that are resistant/insensitive to TKI has informed us 
of the need to target this population to obtain cure [20–22]. 
Nieborowska-Skorska et al., have described elevated 
levels of superoxide in the CD34+CD38− CML precursor 
cells [11], thus establishing reactive oxygen signaling as a 
legitimate target in eliminating CML stem cells [7]. Indeed 
poor responders to TKI therapy accumulated more ROS, 
Figure 3: response of primary cd34+cMl-cP cells to imipramine blue (Ib) in combination with nilotinib. (A) Dot plots 
showing apoptotic response of CML391 to IB (1 µM), nilotinib (1 µM), or combination treatment for 72 h. (b, c) After 72 h treatment with 
drugs or diluent control DMSO /No Drug Control (NDC), primary CML-CP cells were harvested and counted (CML388 (B) and CML391 
(C)). The cells were also stained with Annexin V and/or DAPI for viability. The dot plots shown are from wells treated with the drug 
combination illustrating that some cells counted under phase contrast microscopy and scored as viable owing to Trypan Blue exclusion are 
in fact committing to apoptosis and/or dying. (d) To assess their function after drug treatment, surviving cells were plated into semi-solid 
culture medium for 12 days after which time colony formation was scored for total number. (e) Fluorescence in situ hybridisation (FISH) 
for BCR-ABL1 was performed on plucked colonies. Multiple yellow fusions were seen with K562 cells (positive control for FISH, ×100 
magnification); 2 red and 2 green signals were evident in the normal donor (negative control for FISH, ×40 magnification); 2 red, 2 green, 
1 yellow (fusion) signal as indicated by the arrow were seen in colonies plucked from CFC set up with CML-CP cells from an untreated 
well (CML388, ×100 magnification; this is an unusual but nonetheless positive fusion pattern). CFC from wells treated with 2 µM IB were 
leukemic i.e. BCR-ABL1 positive by FISH (×40 magnification).
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8-oxoG, and γ-H2AX than good responders. Accumulation 
of ROS was independent of proliferation, as elevated 
levels of ROS were found in dormant leukemia cells [11]. 
Further, elevated levels of ROS are not fully normalized 
by TKI and have been shown to cause hypermethylation of 
tumor suppressor genes such as p16ink4a [2, 16].
Treatment with targeted therapies has been 
widely heralded in the clinic, but has also informed 
us that advanced malignancy is not “addicted” to a 
single oncogene or signaling pathway. Both intrinsic 
and extrinsic modes of resistance have been described, 
and redundant as well as multiple signaling pathways 
observed in resistant cells. The continued use of targeted 
therapies likely selects for the expansion of a stem cell 
population resistant to therapies and capable of causing 
rapid recurrence, either in the presence of targeted 
therapy, or once it is discontinued. The relapse rate of 
patients treated with long term TKI has been evaluated 
in the STIM and TWISTER studies. In the TWISTER 
study, patients with undetectable minimal residual disease 
were allowed to discontinue TKI, and a minority (47%) 
did not relapse at 24 months [23]. Similarly in the STIM 
study, discontinuation of TKI led to the majority of 
patients relapsing before 6 months [24]. These studies 
are in the 10–20% of patients with the most favorable 
response; that is CMR for CML. For patients with residual 
disease, discontinuation of TKI is not advised, and these 
patients may have acquired additional mutational burden 
preventing a CMR. Elimination of this population is thus 
an unmet need in treatment of hematopoietic malignancy, 
and the only treatment that has eliminated the stem 
cell population is bone marrow transplantation. Even 
allogeneic bone marrow transplantation, a highly morbid 
procedure, does not guarantee freedom from relapse.
Recent data points towards the signaling pathways 
necessary for the maintenance of leukemic stem cells. 
While cancer stem cells have been shown to have either 
low or elevated levels of ROS, the role of ROS in stem 
cell maintenance appears to be context dependent. In the 
case of myeloid leukemia, the balance of the data supports 
elevated levels of ROS favoring a stem cell phenotype and 
resistance to targeted therapies. Of interest, normal HSC 
in an osteoblastic niche appear to have a phenotype of low 
levels of ROS, elevated levels of notch 1 and N-cadherin, 
with low levels of p38 MAP kinase, p16ink4a and p53 [3]. 
In a model of bone marrow failure in ataxia telangiectasia 
(Atm) null mice, bone marrow exhaustion was associated 
with upregulation of p38MAPK as a reactive oxygen 
response [25]. BCR-ABL1 itself causes increased 
generation of ROS that causes upregulation of Fyn kinase, 
which may also mediate resistance to targeted therapies 
[13]. Thus, in Ph+ myeloid malignancy, the elevated levels 
of ROS in neoplastic stem cells, which is not normalised by 
TKI and in contrast to low levels of ROS in normal HSC, 
may provide a therapeutic window (Figure 9) [2, 14, 17]. 
This difference between normal and malignant stem cells 
may be targeted with an NADPH oxidase inhibitor. Prior 
gene analyses of CML stem cells versus normal HSC 
Figure 4: cell division tracking of primary cMl-cP cells treated in vitro with imipramine blue (Ib) alone or in 
combination with nilotinib. Position of viable CFSEmax cells (undivided; division 0) as guided by Colcemid™ treated control, is shown 
in red in all panels. Cells harvested from the dish having divided once are shown in blue, having undergone two divisions are in orange, 
in division 3 in bright green, in division 4 in dark green, and divided 5 times or more (CFSEnegative cells) in gray. Input was 100 × 103 total 
CML388 CD34+ cells per well. Cells were cultured for 72 h in serum free medium with physiological growth factors with or without 
nilotinib (1 µM) and /or IB (1 µM). It can be seen that the few cells remaining alive after IB treatment, alone or in combination with 
nilotinib, were in early divisions with higher CD34 surface expression. 
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revealed differences in cell cycle genes despite similar 
levels of quiescence [26]. This may be a function of 
differing baseline levels of ROS, with normal HSC being 
driven towards maturation and senescence on elevation of 
ROS, while elevated levels of ROS may favor survival and 
NF-κB elevation in tumor stem cells.
Mechanistically, we found that IB acts as a potent 
PAD [8] as it was capable of strongly reactivating 
the enzymatic activity of the PP2A tumor suppressor 
that, reportedly, is inactive in both CML quiescent 
stem and proliferating progenitor cells [7, 19], and so 
inhibiting NF-κB [15, 27]. Indeed, the pro-apoptotic 
activity of IB and its ability to potentiate the effect of 
TKIs, is consistent with the effect of other PADs in 
TKI-resistant CML stem and progenitor cells [7, 8, 28]. 
The role of PP2A in mediating the effects of IB was 
further elucidated both pharmacologically by using OA 
at a concentration that inhibits PP2A activity only [29], 
and genetically, with sT-Ag, a well studied inhibitor of 
PP2A that binds PP2A catalytic subunit and prevents its 
assembly into a functional multimeric phosphatase [30]. 
Treatment of 32D-BCR-ABL cells with OA blunted the 
apoptotic response to IB, and introduction of sT-Ag nearly 
completely blocked the apoptotic response to IB. This 
suggests that PP2A reactivation plays a major role in the 
activity of IB.
The therapeutic role of NADPH oxidase inhibitors 
in hematopoietic disorders is not fully understood. In our 
Figure 5: response of bcr-Abl1negative cd34+ cells to imipramine blue (Ib) in combination with nilotinib. (A) Primary 
BCR-ABL1negative (normal) CD34+ cells from two donors were treated in culture with nilotinib or IB alone, or nilotinib plus IB in 
combination. After 72 h, cells were stained with Annexin V and DAPI to assess apoptotic response to the drug(s) by flow cytometry. 
White boxes: total Annexin V+ (dead and dying); light grey boxes: total DAPI+ (dead); dark grey boxes: total Annexin V- and DAPI- (most 
viable). (b) After 72 h drug treatment, cells were harvested and plated into semi-solid culture medium for 12 days after which time colony 
forming cells (CFC) were scored for number of individual colonies and type. ‘#CFC’ is the mean of two plates per condition. No significant 
differences in total number of CFC were seen between treatment arms, or with respect to no drug control (NDC) by Student’s t-test. One 
representative result is shown.
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previous study of the NADPH oxidase inhibitor IB in solid 
tumors, we saw striking inhibition of invasion of GBM into 
the brain [31]. As a single agent, IB did not significantly 
extend the lifespan of rats but when combined with the 
conventional chemotherapeutic agent doxorubicin, long 
term survival was noted in all treated animals. A potential 
mechanism of such long term survival is the targeting 
of tumor stem cells, which are resistant to conventional 
chemotherapy alone. This finding illustrates a potential 
cardinal principle in the use of NADPH oxidase inhibitors; 
whilst they may not be highly effective as monotherapy, 
in combination with a targeted agent and/or conventional 
chemotherapy, their potency is realized. In leukemia, this 
may in part reflect the complex microenvironment in 
which macrophages, locally produced growth factors, and 
stromal cells support neoplastic leukemia cells [32–40].
Figure 6: Imipramine blue (Ib) blocks nF-κb activation in Ph+ cells. KBM-5 (2 × 106/mL) cells treated with IB for 12 h and 
then exposed with 0.1 nM TNF-α for 30 minutes. Cells were harvested, nuclear extract prepared and EMSA performed. Numbers below 
figure are fold changes relative to the untreated control.
Figure 7: Imipramine blue (Ib) acts as a PAd in 32d-bcr-Abl cells. PP2A phosphatase activity (pmole phosphate/min) 
was assessed in untreated 32D-BCR-ABL cells and upon 6 h exposure to IB at concentration of 5 μM. The PAD, FTY720 (2.5 µM), was 
included as a positive control. Student’s t tests were performed using GraphPad Prism version 6.0a with a P value < 0.05 being considered 
significant.
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Signaling in tumor stem cells is associated 
with elevated levels of NF-κB signaling [41, 42], 
which prevents tumor apoptosis at a number of levels, 
including increased expression of drug efflux pumps, 
as well as production of inflammatory cytokines that 
promote stromal-tumor interactions. Increasing evidence 
from the clinic demonstrates that tumors with stem 
cell characteristics, such as CML, gain independence 
from original driver mutations. So once again CML 
is a paradigm for cancer therapy highlighting the 
need for complementary agents targeting alternative 
signaling pathways. We demonstrate that IB, an agent in 
preclinical development, kills CML cells with stem cell 
characteristics. Combination therapy of TKI and IB may 
be of benefit in the treatment of CML as well as other 
ROS-driven hematopoietic malignancies with driver 
oncogenic fusions and associated genomic instability, 
through targeting NADPH oxidase.
Figure 8: PP2A mediates the pro-apoptotic activity of imipramine blue (Ib) in 32dcl3 and 32d-bcr-Abl1 cells. 
(A) Effect of IB on viability of wild type and small T antigen (sT-Ag)-expressing 32D-BCR-ABL1 cells. Note that both 0.25 nM OA 
treatment and sT-Ag expression results in suppression of PP2A phosphatase activity. (b) IB pro-apoptotic activity, assessed as percentage 
of AnnexinV+ cells, in parental and BCR-ABL1-expressing 32Dcl3 exposed to 0.25 nM of OA, and combination. Student’s t tests were 
performed using GraphPad Prism version 6.0a with a P value < 0.05 being considered significant.
Figure 9: Proposed mechanism of nAdPH oxidase. Elevated levels of ROS in neoplastic stem cells, which is not normalised by 
TKI and in contrast to low levels of ROS in normal HSC, may provide a therapeutic window.
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MAterIAls And MetHods
Primary human cell samples
Primary cells were obtained with informed 
consent according to the Declaration of Helsinki, from 
peripheral blood or leukapheresis product of patients 
newly diagnosed with CML in CP, or lymphoma 
patients without bone marrow involvement as 
BCR-ABL1negative normal controls. Cells were either first 
enriched by positive selection by magnetically activated 
cell separation (CliniMACS) to > 90% CD34+ cells or 
immediately cryopreserved as total mononuclear cells. 
Once the latter were thawed, viable cells were enriched to 
> 90% CD34+ cells after staining with anti-CD34 antibody 
by fluorescence activated cell sorting using a FACSAria 
flow cytometer (BD Biosciences). The study had approval 
from the West of Scotland Research Ethics Committee 4.
cell lines
KCL22, K562, KBM-5, HL60 cell lines are 
widely published in vitro models of human leukemia, 
their selection for use being dependent on availability in 
a particular laboratory. In this study, KCL22WT, K562 
and HL60 were commercially sourced from cell culture 
collections (ECACC or DMSZ German Collection 
of Microorganisms and Cell Cultures). KCL22T315I 
cells were kindly provided by Dr Nicholas J. Donato 
(University of Michigan) [43]. The parental human 
BCR-ABL1+ CML-BC cell line, KCL22 [44], derived 
from the pleural effusion of a 32 year old female patient, 
is hyperdiploid karyotype with 3.3% polyploidy (DSMZ 
#ACC 519). Basophilic, erythroblastic hypotriploidy 
K562 cell line was derived from the pleural effusion 
of 53 year old female patient in BC with genomic 
mutations in p53 and CDKN2a according to the Sanger 
COSMIC database (DSMZ #ACC 10) [45]. KBM-5 
cells derived at the MD Anderson from a 67 year old 
female patient carries multiple copies of the Ph and 
chromosomes 7, 8, 15, and 17 [46]. HL60 (#ACC 3) 
is of hypotetraploid karyotype with 1.5% polyploidy 
derived from the peripheral blood of a 36-year-old 
female with acute promyelocytic leukemia [47].
cell culture
Primary human cells were cultured in vitro 
in physiological (for CML) or high (for normal) 
concentration growth factor (GF)-supplemented 
serum-free medium as previously described [26]. Cell 
lines (KCL22WT/T315I, K562, KBM-5) were cultured in 
RPMI1640 supplemented with 10% fetal bovine serum 
(FBS), 50 U/mL penicillin, 50 mg/mL streptomycin, 
and 2 mM L-glutamine (Invitrogen) at 37ºC, 5% CO2. 
The 32D-BCR-ABL, 32D-BCR-ABL1-GFP–sT-Ag 
and parental 32Dcl3 mouse myeloid progenitors were 
maintained in culture in Iscove’s modified Dulbecco 
medium (IMDM), 10% FBS, and 2 mM L-glutamine, 
2 ng/mL murine IL-3, 50 U/mL penicillin and 50 mg/mL 
streptomycin. 
Flow cytometry (apoptosis, cell division tracking)
Following treatment with various concentrations 
of IB and/or nilotinib in vitro, primary CML-CP cells 
were harvested, surface stained with anti-CD34-
allophycocyanin (APC) for maturity followed by Annexin 
V-phycoerythrin (PE) and propidium iodide or 4ʹ,6-
diamidino-2-phenylindole (DAPI) as markers of apoptosis, 
and then acquired using a FACSCanto II flow cytometer 
(BD Biosciences). For cell division tracking, cells were 
first stained with carboxyfluorescein isothiocyanate 
(CFSE) as previously described [48]. 
After 24 h drug treatments, parental/BCR-ABL1 
expressing 32Dcl3 cells were washed once in PBS, then 
once in Annexin V binding buffer before resuspending 
to 1 × 106 cells/mL. Five microlitres of fluorochrome-
conjugated Annexin V was added per 100 μL of cell 
suspension followed by 15 minutes incubation at room 
temperature then reading by BD LSR II cell analyzer.
colony forming cell assay
Clonogenicity of surviving cells was assayed 
in semi-solid culture medium (MethoCult H4034 
Optimum, Stem Cell Technologies) for 12 days. Briefly, 
the methylcellulose was seeded with a fixed volume or 
3,000 viable cells and plated onto 35 mm culture dishes. 
Colonies were counted and scored as colony forming unit 
(CFU)-erythroid (E), CFU-granulocyte, -macrophage, 
-granulocyte/macrophage (G, M, G/M), CFU-granulocyte, 
erythrocyte, macrophage, megakaryocyte (GEMM) or 
burst forming unit-erythroid (BFU-E).
PP2A assay
PP2Ac assays from whole cell lysates were carried 
out as described [9] using the PP2Ac immunoprecipitation 
(IP) phosphatase assay kit (Millipore). Briefly, protein 
lysate (50 μg) in 100 μL of 20 mM Hepes, pH 7.0/100 mM 
NaCl, 5 μg of PP2Ac antibody (Millipore), and 25 μL of 
Protein A–agarose were added to 400 μL of 50 mM Tris, 
pH 7.0/100 mM CaCl2, and IPs were carried out at 4°C for 
2 h. IPs were washed and used in the phosphatase reaction 
according to the manufacturer’s protocol. As an internal 
control, the amount of IP PP2A was also monitored by 
anti-PP2Ac Western blots (data not shown). Both OA 
treatment and sT-Ag expression as procedures to inhibit 
PP2A activity have been previously described [9, 19]. 
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electrophoretic mobility shift assay (eMsA) 
To assess NF-κB activation, we isolated 
nuclei from KBM-5 cell lines and carried out EMSA 
essentially as previously described [22]. In brief, nuclear 
extracts prepared from KBM-5 cells (2 × 106/mL) 
were incubated with 32P-end-labeled 45-mer double-
stranded NF-κB oligonucleotide (4 µg of protein with 
16 fmol of DNA) from the HIV long terminal repeat 
(5ʹ-TTGTTACAAGGGACTTTCCGCTG GGGACTTTC 
CAGGGA GGCGT GG-3ʹ) for 30 min at 37°C. The 
resulting DNA–protein complex was separated from free 
oligonucleotides on 6.6% native polyacrylamide gels. The 
dried gel was exposed to x-ray film and quantitated by 
Image J software.
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